Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial of atezolizumab in pediatric and young adult participants with solid tumors was terminated; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• Atezolizumab (atezolizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Solid Tumor | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2020-02-25